Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPremera Bluecross Prostate Drug Coverage | OpenPay…
    Ask Trek AI about this page
    ModifiedPremera BluecrossPolicy N/A

    Prostate Cancer Oral and Intravenous Drug Coverage Criteria

    Customize your policy alerts

    Sign up for all Premera Bluecross policy alerts

    Know when Premera Bluecross releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and prior authorization criteria for selected oral and intravenous medications used to treat advanced prostate cancer, including drug-specific indications, combination therapy, prior treatment, step therapy, site of care, and continuation requirements.

    Policy Summary
    PayerPremera Bluecross
    PolicyProstate Cancer Oral and Intravenous Drug Coverage Criteria
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateSeptember 1, 2026
    Last ReviewAug 11, 2026
    Next Review DateN/A
    Key ActionSubmit office notes and medical records documenting the diagnosis, treatment history, medical necessity, and continued clinical response when requesting authorization.
    SourceLink
    POLICY UPDATE CHANGES

    Added coverage criteria for Abirtega, generic abiraterone, and Zytiga in combination with capivasertib.

    Added coverage for Akeega in BRCA2-mutated metastatic castration-sensitive prostate cancer.

    Changed the initial authorization period for listed oral drugs from 3 months to 6 months.

    Added an androgen deprivation therapy requirement for specified abiraterone, darolutamide, and apalutamide products.

    Removed the step requirement for Zytiga before Xtandi.

    Added and expanded coverage criteria for Yonsa, Nubeqa, and Erleada.

    Added new indications and NCCN recommendations for Xtandi.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    7
    Oral drugs managed through pharmacy benefit
    1 IVDrug managed through medical benefit
    6 monthsInitial authorization period
    12 monthsReauthorization period
    2026Latest policy update
    N/AMedicare Advantage

    Drug-Specific Coverage Criteria

    Abirtega and generic abiraterone

    Medically necessary when all applicable criteria are met.

    Abirtega (abiraterone) or generic abiraterone

    • ONE of the following diagnoses

      • Metastatic castration-resistant prostate cancer.
      • Deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer.
      • PTEN-deficient metastatic androgen pathway modulation-naive or sensitive prostate cancer, when used in combination with capivasertib.
    • ONE of the following androgen-deprivation therapy requirements

      • Concurrent treatment with a gonadotropin-releasing hormone (GnRH) analog.
      • Prior bilateral orchiectomy.
    • The medication is used in combination with prednisone.

    Akeega

    Akeega is medically necessary when all criteria are met.

    Akeega (niraparib and abiraterone acetate)

    • ONE of the following diagnoses

      • Deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer.
      • Deleterious or suspected deleterious BRCA2-mutated metastatic castration-sensitive prostate cancer.
    • ONE of the following androgen-deprivation therapy requirements

      • Concurrent treatment with a gonadotropin-releasing hormone (GnRH) analog.
      • Prior bilateral orchiectomy.

    Erleada

    Erleada is medically necessary when all criteria are met.

    Erleada (apalutamide)

    • ONE of the following diagnoses

      • Metastatic castration-sensitive prostate cancer.
      • Non-metastatic castration-resistant prostate cancer.
    • ONE of the following androgen-deprivation therapy requirements

      • Concurrent treatment with a gonadotropin-releasing hormone (GnRH) analog.
      • Prior bilateral orchiectomy.

    Nubeqa

    Nubeqa is medically necessary when all criteria are met.

    Nubeqa (darolutamide)

    • ONE of the following diagnoses

      • Non-metastatic castration-resistant prostate cancer.
      • Metastatic castration-sensitive prostate cancer.
      • Metastatic castration-sensitive prostate cancer in combination with docetaxel.
    • ONE of the following androgen-deprivation therapy requirements

      • Concurrent treatment with a gonadotropin-releasing hormone (GnRH) analog.

    Xtandi

    Xtandi is medically necessary when all criteria are met.

    Xtandi (enzalutamide)

    • ONE of the following diagnoses or treatment settings

      • Castration-resistant prostate cancer.
      • Metastatic castration-sensitive prostate cancer.
      • Adult individual with HRR gene-mutated metastatic castration-resistant prostate cancer, when Xtandi is used in combination with Talzenna (talazoparib).
      • Non-metastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis.
    • ONE of the following androgen-deprivation therapy requirements

    Yonsa

    Yonsa is medically necessary when all criteria are met.

    Yonsa (abiraterone)

    • Metastatic castration-resistant prostate cancer.
    • ONE of the following androgen-deprivation therapy requirements

      • Concurrent treatment with a gonadotropin-releasing hormone (GnRH) analog.
      • Prior bilateral orchiectomy.
    • Yonsa is used in combination with methylprednisolone or another corticosteroid.
    • The individual has tried and had an inadequate response or intolerance to Abirtega (abiraterone) or generic abiraterone.

    Zytiga

    Zytiga is medically necessary when all criteria are met.

    Zytiga (abiraterone)

    • ONE of the following diagnoses or treatment settings

      • Metastatic castration-resistant prostate cancer.
      • Deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer, when used in combination with Lynparza (olaparib).
      • Metastatic high-risk castration-sensitive prostate cancer.
      • PTEN-deficient metastatic androgen pathway modulation-naive or sensitive prostate cancer, when used in combination with capivasertib.
    • The individual has tried and had an inadequate response or intolerance to Abirtega (abiraterone) or generic abiraterone.

    Jevtana

    Jevtana is medically necessary when all stated criteria are met.

    Jevtana (cabazitaxel) IV

    • Metastatic castration-resistant prostate cancer.
    • Jevtana is used in combination with prednisone.
    • The individual has been previously treated with a docetaxel- [the available document text is truncated at this point].

    This medical policy does not apply to Medicare Advantage.

    Initial Authorization Criteria

    Initial authorization

    Initial authorization may be approved for up to 6 months when all applicable drug-specific criteria are met.

    Drug-specific initial authorization

    • The individual meets the applicable clinical indication, combination-therapy, androgen-deprivation, corticosteroid, prior-treatment, and other coverage requirements for the requested drug.

      See the applicable medication-specific criteria.

    Reauthorization Criteria

    Reauthorization

    All drugs listed in this policy may be reauthorized for up to 12 months when all continuation requirements are met.

    Continuation therapy

    • The drug-specific coverage criteria continue to be met.
    • Chart notes demonstrate that the individual continues to show a positive clinical response to therapy.

    Required Prior Therapies

    StepRequested therapyPrior therapy requirement
    1Yonsa (abiraterone) or Zytiga (abiraterone)Try Abirtega (abiraterone) or generic abiraterone first; inadequate response or intolerance is required.
    StepRequested therapyPrior therapy requirement
    1Jevtana (cabazitaxel)The individual has been previously treated with a docetaxel-
    StepRequested therapyPrior therapy requirement
    1Xtandi (enzalutamide)The previously required step of Zytiga (abiraterone acetate) before Xtandi (enzalutamide) was removed.

    Authorization and Documentation Requirements

    Prior Authorization

    Initial Authorization Required

    Prior authorization is required for the listed prostate cancer medications. When the applicable coverage criteria are met, initial approval may be granted for up to 6 months.

    • Applies to the medications listed in this policy.
    • Document that all drug-specific medical-necessity criteria are satisfied.
    Prior Authorization

    Reauthorization and Continued Response

    Reauthorization may be granted for up to 12 months when the drug-specific coverage criteria continue to be met and chart notes demonstrate that the individual continues to show a positive clinical response to therapy.

    • Submit current chart notes with each continuation request.
    • Document ongoing response to therapy.

    Billing and Coding

    Covered HCPCS CodesHCPCSCovered
    J9043Injection, cabazitaxel (Jevtana), 1 mg

    Benefit and Site-of-Care Management

    Billing Rule

    Bill listed oral drugs under the pharmacy benefit

    Abirtega, Akeega, Erleada, Nubeqa, Xtandi, Yonsa, and Zytiga are managed through the pharmacy benefit.

    Billing Rule

    Bill Jevtana under the medical benefit

    Jevtana (cabazitaxel) is managed through the medical benefit.

    Clinical Background

    Prostate cancer is a neoplastic disease arising from mutations in prostate cells. Its development and progression are influenced by androgen biosynthesis, which produces hormones that support prostate-cancer growth, and by androgen-receptor signaling, through which cancer cells respond to those hormones.

    Most prostate cancers initially respond to androgen-deprivation therapy. However, some disease progresses despite local treatment and first-line hormonal therapy even when testosterone remains at castrate levels; this state is called castration-resistant prostate cancer. Disease that remains localized or regional has a cited five-year survival rate of effectively 100%, compared with 31% when distant metastases are present.

    Clinical Definitions

    Castration-Resistant Prostate Cancer
    Disease stateCastration-resistant prostate cancer (CRPC)
    ProgressionProstate cancer that has progressed despite local therapy and first-line hormonal therapy.
    Testosterone statusProgression occurs while testosterone remains at castrate levels.
    Prostate Cancer Disease-State Categories
    Metastatic castration-resistant prostate cancer (mCRPC)Castration-resistant prostate cancer with metastatic disease.
    Metastatic castration-sensitive prostate cancer (mCSPC)Metastatic prostate cancer that remains sensitive to androgen deprivation therapy.
    Policy Summary
    PayerPremera Bluecross
    PolicyProstate Cancer Oral and Intravenous Drug Coverage Criteria
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateSeptember 1, 2026
    Last ReviewAug 11, 2026
    Next Review DateN/A
    Key ActionSubmit office notes and medical records documenting the diagnosis, treatment history, medical necessity, and continued clinical response when requesting authorization.
    SourceLink
    On This Page
    Drug-Specific Coverage CriteriaInitial Authorization CriteriaReauthorization CriteriaRequired Prior TherapiesAuthorization and Documentation RequirementsBilling and CodingBenefit and Site-of-Care ManagementClinical BackgroundClinical Definitions
    Akeega is used in combination with prednisone.
    Prior bilateral orchiectomy.
    Concurrent treatment with a gonadotropin-releasing hormone (GnRH) analog.
  1. Prior bilateral orchiectomy.
  2. ONE of the following androgen-deprivation therapy requirements

    • Concurrent treatment with a gonadotropin-releasing hormone (GnRH) analog.
    • Prior bilateral orchiectomy.
  3. Zytiga is used in combination with prednisone.
  4. Documentation Required

    Androgen Deprivation Therapy Required

    Document that generic abiraterone, Zytiga, Yonsa, Nubeqa, and Erleada are being used in combination with androgen deprivation therapy (ADT).

    • Document concurrent receipt of a gonadotropin-releasing hormone (GnRH) analog, or prior bilateral orchiectomy.
    • The required ADT combination applies to generic abiraterone, Zytiga (abiraterone), Yonsa (abiraterone), Nubeqa (darolutamide), and Erleada (apalutamide).
    Prior Authorization

    Initial Authorization and FDA Dosing

    For other listed oral drugs, initial authorization may be granted for up to 6 months. Use must also follow the applicable product's US Food and Drug Administration (FDA) dosage and administration prescribing information.

    • Document dosing and administration consistent with the applicable FDA prescribing information.
    Step Therapy

    Abiraterone Product Step Therapy

    Yonsa and Zytiga require a prior trial of Abirtega (abiraterone) or generic abiraterone with an inadequate response or intolerance before coverage may be considered.

    • Document the prior Abirtega or generic abiraterone trial.
    • Document inadequate response or intolerance.
    Prior Authorization

    Prior Docetaxel Treatment Required

    Jevtana (cabazitaxel) must be used in combination with prednisone, and the individual must have been previously treated with a docetaxel-

    • Document the prior docetaxel treatment while preserving the source wording: “previously treated with a docetaxel-”.
    Documentation Required

    Medical Records and Office Notes

    Submit medical records demonstrating that medical-necessity criteria are met for the condition under review.

    • Office visit notes containing the diagnosis, relevant history, physical evaluation, and medication history.
    • Include other related medical records needed to support the request.
    Documentation Required

    Document Continued Positive Response

    Continuation requests must include chart notes demonstrating that the individual continues to show a positive clinical response to therapy.

    • Provide current clinical response documentation with reauthorization requests.
    Denial Risk

    Non-Policy Uses May Be Denied

    All other uses of the medications listed in this policy are considered investigational and may be denied.

    • Confirm that the requested use matches a covered policy indication.
    Denial Risk

    Insufficient Response Documentation

    Continuation authorization requires the drug-specific coverage criteria to remain met and documentation of a positive clinical response. Requests without sufficient response documentation may not be approved.

    • Submit chart notes supporting continued clinical benefit.
    • Reauthorization may be denied when criteria are no longer met or positive response is not documented.
    Non-metastatic castration-resistant prostate cancer (nmCRPC)
    Castration-resistant prostate cancer without metastatic disease.
    Non-metastatic castration-sensitive prostate cancerNon-metastatic prostate cancer that remains sensitive to androgen deprivation therapy; the policy identifies biochemical recurrence at high risk for metastasis as a covered disease state for Xtandi.
    Castration-Resistant Prostate Cancer
    Disease stateCastration-resistant prostate cancer (CRPC)
    Required progressionDisease has progressed despite local therapy and first-line hormonal therapy.
    Castrate testosteroneThe disease progresses while testosterone remains at castrate levels.
    Metastatic Castration-Resistant Prostate Cancer
    DefinitionMetastatic castration-resistant prostate cancer (mCRPC) is castration-resistant prostate cancer with metastatic disease.
    HRR-mutated subgroupThe policy addresses HRR gene-mutated mCRPC, including treatment with Xtandi in combination with Talzenna.
    BRCA-mutated subgroupThe policy addresses deleterious or suspected deleterious BRCA-mutated mCRPC, including treatment options involving Akeega.
    Metastatic Castration-Sensitive Prostate Cancer
    DefinitionMetastatic castration-sensitive prostate cancer (mCSPC) is metastatic prostate cancer that remains sensitive to androgen deprivation therapy.
    Disease settingThe policy identifies mCSPC as a metastatic prostate cancer disease state distinct from metastatic castration-resistant disease.
    HRR-mutated contextThe policy discusses HRR gene-mutated mCSPC in connection with Akeega treatment studies.
    HRR Gene-Mutated Disease
    DefinitionHRR gene-mutated (HRRm) prostate cancer has a pathogenic alteration in a homologous recombination repair gene.
    Testing contextHRR gene mutation status may be determined using circulating tumor DNA next-generation sequencing assays or solid tumor tissue.
    Policy relevanceHRR gene-mutated disease is addressed in metastatic castration-resistant prostate cancer treatment recommendations.
    HRR Gene Mutations Relevant to Talzenna Selection
    Genes 1–4ATM, ATR, BRCA1, and BRCA2.
    Genes 5–8CDK12, CHEK2, FANCA, and MLH1.
    Genes 9–12MRE11A, NBN, PALB2, and RAD51C.